260 related articles for article (PubMed ID: 21361868)
1. Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders.
Paba S; Frau R; Godar SC; Devoto P; Marrosu F; Bortolato M
Curr Pharm Des; 2011; 17(2):151-67. PubMed ID: 21361868
[TBL] [Abstract][Full Text] [Related]
2. A review on steroidal 5α-reductase inhibitors for treatment of benign prostatic hyperplasia.
Sun J; Xiang H; Yang LL; Chen JB
Curr Med Chem; 2011; 18(23):3576-89. PubMed ID: 21756226
[TBL] [Abstract][Full Text] [Related]
3. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
4. Potency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5alpha-reductase II.
Pais P
Adv Ther; 2010 Aug; 27(8):555-63. PubMed ID: 20623347
[TBL] [Abstract][Full Text] [Related]
5. 5alpha-reductase activity in the prostate.
Steers WD
Urology; 2001 Dec; 58(6 Suppl 1):17-24; discussion 24. PubMed ID: 11750244
[TBL] [Abstract][Full Text] [Related]
6. 5α-reductase type 3 enzyme in benign and malignant prostate.
Titus MA; Li Y; Kozyreva OG; Maher V; Godoy A; Smith GJ; Mohler JL
Prostate; 2014 Feb; 74(3):235-49. PubMed ID: 24150795
[TBL] [Abstract][Full Text] [Related]
7. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
Traish AM; Melcangi RC; Bortolato M; Garcia-Segura LM; Zitzmann M
Rev Endocr Metab Disord; 2015 Sep; 16(3):177-98. PubMed ID: 26296373
[TBL] [Abstract][Full Text] [Related]
8. Targeting 5α-reductase for prostate cancer prevention and treatment.
Nacusi LP; Tindall DJ
Nat Rev Urol; 2011 May; 8(7):378-84. PubMed ID: 21629218
[TBL] [Abstract][Full Text] [Related]
9. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
Tindall DJ; Rittmaster RS
J Urol; 2008 Apr; 179(4):1235-42. PubMed ID: 18280514
[TBL] [Abstract][Full Text] [Related]
10. Role of 5α-reductase inhibitors in benign prostatic diseases.
Azzouni F; Mohler J
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):222-30. PubMed ID: 22333687
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases.
Cabeza M; Sánchez-Márquez A; Garrido M; Silva A; Bratoeff E
Curr Med Chem; 2016; 23(8):792-815. PubMed ID: 26861003
[TBL] [Abstract][Full Text] [Related]
12. Human osteoblast-like cells express predominantly steroid 5alpha-reductase type 1.
Issa S; Schnabel D; Feix M; Wolf L; Schaefer HE; Russell DW; Schweikert HU
J Clin Endocrinol Metab; 2002 Dec; 87(12):5401-7. PubMed ID: 12466325
[TBL] [Abstract][Full Text] [Related]
13. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
[TBL] [Abstract][Full Text] [Related]
14. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride.
Ranjan M; Diffley P; Stephen G; Price D; Walton TJ; Newton RP
Life Sci; 2002 May; 71(2):115-26. PubMed ID: 12031682
[TBL] [Abstract][Full Text] [Related]
16. 5α-Reduced glucocorticoids: a story of natural selection.
Nixon M; Upreti R; Andrew R
J Endocrinol; 2012 Feb; 212(2):111-27. PubMed ID: 21903862
[TBL] [Abstract][Full Text] [Related]
17. Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases.
Salvador JA; Pinto RM; Silvestre SM
J Steroid Biochem Mol Biol; 2013 Sep; 137():199-222. PubMed ID: 23688836
[TBL] [Abstract][Full Text] [Related]
18. A new label-free screen for steroid 5α-reductase inhibitors using LC-MS.
Srivilai J; Rabgay K; Khorana N; Waranuch N; Nuengchamnong N; Ingkaninan K
Steroids; 2016 Dec; 116():67-75. PubMed ID: 27789379
[TBL] [Abstract][Full Text] [Related]
19. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
Rittmaster RS
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
[TBL] [Abstract][Full Text] [Related]
20. Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.
Li Z; Alyamani M; Li J; Rogacki K; Abazeed M; Upadhyay SK; Balk SP; Taplin ME; Auchus RJ; Sharifi N
Nature; 2016 May; 533(7604):547-51. PubMed ID: 27225130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
